Previously, medical treatments and drugs were designed for an 'average patient'. This may provide success for some patients, but not for others. Today, the importance to step away from a 'one-size-fits-all' approach however, has become clear. And we aim for a much more effective approach that takes into account the differences between individuals, their genes, environments, lifestyles, all of which also influences their individual responses to treatment.

This calls for a thorough understanding of diseases, at the system-level, and is aimed at predicting the modulation of disease networks by drugs in cells, organs, and the body as a whole. To achieve this, we gather metabolomics data from patients and preclinical in-vitro models that are derived from patients (organ-on-a-chip models using human iPSC derived cells) or in-vivo data which we integrate into systems pharmacology modelling.

Our new strategies on pharmacology and personalised medicine development, require further clinical collaborations to help us optimizing and validating. In the end, to result in concepts of system therapeutics.